Survival Rate and Prognosis for Bone Cancer

• The combined 5-year relative survival rate across all primary bone and joint cancer types and stages is 68.7%, based on SEER data for people diagnosed between 2016 and 2022 — but this single number hides large differences by subtype and stage.
• Per the PDQ osteosarcoma treatment summary, stage changes the outlook substantially: osteosarcoma confined to the bone and treated with surgery plus chemotherapy has roughly a 62-65% chance of 5-year survival, versus roughly 30% once the disease has spread at diagnosis (about 45% in the EURAMOS trial).
• Per the Ewing sarcoma PDQ summary, in the COG-AEWS1031 trial, 5-year overall survival for localized Ewing sarcoma was 88%; for children and adolescents overall, Ewing sarcoma 5-year survival now ranges from about 69% to 85% depending on age group, up sharply from 20-59% decades ago.
• Grade, patient age, tumor location and size, and how well the tumor responds to initial treatment all shape an individual’s outlook beyond subtype and stage alone.
• Long-term follow-up care supports early detection of recurrence and helps preserve the survival gains achieved through modern multidisciplinary treatment.

What is the Survival Rate for Bone Cancer?

When discussing the survival rate for bone cancer, it’s important to understand that these statistics represent averages across large groups of patients and do not predict an individual’s outcome. Primary bone cancer is relatively rare, and its prognosis is influenced by numerous variables, including which specific type of bone cancer is involved.

Overall 5-Year Survival Statistics

Bone cancer outcomes are most commonly summarized as a 5-year relative survival rate, a measure that compares how people with the cancer fare against similar people in the general population who do not have it. According to SEER, the cancer registry program run by the National Cancer Institute, the combined 5-year relative survival rate across all primary bone and joint cancer types and stages is 68.7% for people diagnosed between 2016 and 2022. This all-types, all-stages figure is only a starting point — as the sections below show, the outlook for a specific bone cancer type and stage can run considerably higher or lower than this average.

These figures reflect people diagnosed in past years, so they may lag behind the benefit of more recent treatment advances.

Understanding Survival Rate Percentages

As SEER explains, a relative survival figure isolates deaths attributable to the cancer itself, setting aside the chance of dying from unrelated causes. So a 70% five-year relative survival rate means people with that diagnosis are, on average, about 70% as likely to be alive five years later as similar people without the cancer — it is a population comparison, not a simple headcount of survivors. Because these numbers come from large groups diagnosed years earlier, they cannot forecast what will happen to any one person, and they may not capture the effect of treatments introduced more recently.

Care planning stays centered on the individual: clinicians combine these population statistics with a patient’s own tumor characteristics and health to guide treatment aimed at maximizing that person’s own chances of survival with bone cancer.

Key Factors Influencing Bone Cancer Prognosis

Several critical factors play a significant role in determining the prognosis for bone cancer patients. These elements help medical teams tailor treatment plans and provide a more accurate assessment of an individual’s outlook.

Cancer Stage and Grade

Bone sarcomas are typically classified as localized or metastatic rather than through the lymph-node-based staging used for many other cancers, since they spread through the lymphatic system far less often:

• Localized: The tumor is confined to the bone where it started, sometimes with limited extension into nearby tissue. Patients with localized disease generally have the most favorable outcomes.
• Metastatic (Distant): The cancer has reached distant sites, most often the lungs or other bones. This stage carries a lower survival outlook, and having metastatic disease already present at diagnosis is one of the strongest predictors of a harder course.

Grade describes how abnormal the tumor cells look under a microscope and how fast they tend to grow: lower-grade tumors tend to grow more slowly and carry a more favorable prognosis, while higher-grade tumors are more likely to grow and spread quickly.

Osteosarcoma, a common primary bone cancer, illustrates how much stage alone can shift the numbers:

Stage of Osteosarcoma	Approximate 5-Year Overall Survival
Localized, treated with surgery and chemotherapy	62-65%
Metastatic disease present at diagnosis	About 30% (45% in the EURAMOS trial)

(Source: National Cancer Institute PDQ Osteosarcoma treatment summary. EURAMOS is the European and American Osteosarcoma Study, an international trial.)

Patient Age and General Health

Other factors significantly influencing bone cancer prognosis include:

• Age: Younger patients, particularly children and adolescents, often have better outcomes, in part because they can typically tolerate more intensive treatment. Older adults may have other health conditions that complicate care.
• General Health: Other medical conditions a patient may have can limit how well they tolerate intensive treatments such as chemotherapy and surgery, which in turn affects their chances of survival.
• Tumor Location and Size: Tumors in places that allow complete surgical removal generally carry a better outlook. Larger tumors, or those in harder-to-reach areas such as the spine or pelvis, can be more difficult to treat effectively.
• Response to Treatment: How well the tumor shrinks with initial chemotherapy, given before surgery, is one of the strongest indicators of long-term survival in both osteosarcoma and Ewing sarcoma.

Survival Outlook by Bone Cancer Type

Primary bone cancer is not a single disease; it covers several distinct types, each with its own typical patient population and survival outlook. Understanding bone cancer prognosis means looking at the specific type involved, which is why the combined 68.7% figure from SEER above is only a starting point.

Survival by Specific Bone Cancer Types

• Osteosarcoma: The most common primary bone cancer, typically diagnosed in children, teenagers, and young adults, usually starting in the long bones of the arms or legs. Over the past several decades, 5-year relative survival has improved substantially, per SEER: it now stands at roughly 72% among patients diagnosed before age 15 (up from about 40% historically) and around 71% among those diagnosed between ages 15 and 19 (up from about 56%). Patients whose disease is still localized when treated with surgery and chemotherapy have about a 62-65% chance of 5-year survival; when metastatic disease is already present at diagnosis, roughly 30% survive 5 years, and about 45% did so in the international EURAMOS trial.
• Ewing Sarcoma: The second most common primary bone cancer in children and young adults, most often found in the pelvis, femur, or ribs. Survival has climbed even more sharply here, per the Ewing sarcoma PDQ: 5-year rates now reach 80-85% among patients diagnosed before age 15 (up from about 59% historically) and roughly 69% among those diagnosed between ages 15 and 19 (up from about 20%). In the COG-AEWS1031 trial of patients with localized disease, including those with large tumors or a poor early response, 5-year overall survival was 88%. Roughly 1 in 4 patients has metastatic disease at diagnosis, which is considered the single strongest factor pointing toward a harder course; outcomes tend to be better when the spread is confined to the lungs than when it also reaches bone or bone marrow.
• Chondrosarcoma: This cancer forms in cartilage and mainly affects adults over 40, most often in the pelvis, upper leg, or shoulder. It typically grows slowly, though some tumors grow and spread more quickly. Grade and how completely surgeons can remove the tumor are the main drivers of outcome; a site-specific 5-year survival percentage for chondrosarcoma comparable to the osteosarcoma and Ewing sarcoma figures above was not available in the sources reviewed for this article.
• Chordoma: A very rare, usually slow-growing cancer that forms in the bones of the spine, most often at the base of the skull or at the sacrum, typically in older adults. Its location can make it difficult to treat, and recurrence after treatment is a recognized concern. Outlook depends on factors such as the patient’s age, exactly where along the spine the tumor formed, and how it responds to treatment; an overall 5-year survival percentage for chordoma was not available in the sources reviewed for this article.

These differences among bone cancer types are why accurate diagnosis and type-specific treatment planning matter so much for long-term survival.

Treatment Advances and Long-Term Survival

Advances in treatment strategy have driven much of the survival improvement described above, particularly for osteosarcoma and Ewing sarcoma.

Impact of Modern Therapies

Modern bone cancer treatment typically combines several approaches:

• Surgery: Advances in surgical technique, including limb-sparing procedures, allow removal of the tumor while preserving the affected limb in many cases.
• Chemotherapy: Given both before surgery to shrink the tumor and afterward to target any remaining cancer cells, chemotherapy has been central to the survival gains seen in osteosarcoma and Ewing sarcoma.
• Radiation Therapy: Precisely targeted radiation can destroy cancer cells when surgery isn’t feasible, or reach areas where cancer may remain, and plays a particularly frequent role in Ewing sarcoma care.
• Targeted and Emerging Therapies: Newer approaches continue to be studied for certain bone cancers, though the survival figures in this article mainly reflect outcomes with standard surgery, chemotherapy, and radiation.

Role of Follow-Up Care

Long-term follow-up is an important part of managing bone cancer after initial treatment. This typically includes regular imaging, blood tests, physical examinations, and rehabilitation support as needed. Consistent follow-up helps catch recurrence early and supports the survival trends described in this article.

Frequently Asked Questions

What is the average bone cancer life expectancy?

Across all primary bone cancer types and stages combined, the 5-year relative survival rate is 68.7%, per SEER data. That combined figure hides wide variation: localized osteosarcoma or Ewing sarcoma carries a 5-year survival estimate in the 62-88% range, while metastatic disease at diagnosis is associated with meaningfully lower survival. Individual outlook also depends on tumor grade, patient age, and how well the cancer responds to treatment.

How do treatment options affect chances of survival with bone cancer?

Multidisciplinary treatment — typically surgery combined with chemotherapy, and radiation therapy in some cases — has driven the survival improvements seen over recent decades, especially for osteosarcoma and Ewing sarcoma. How well a tumor shrinks with initial chemotherapy is one of the strongest predictors of long-term outcome.

Are bone cancer survival rates improving over time?

Yes, according to the PDQ treatment summaries, for the two most common primary bone cancers in children and young adults. Osteosarcoma 5-year survival has climbed from about 40-56% to roughly 71-72%, and Ewing sarcoma 5-year survival has climbed from about 20-59% to 69-85%, depending on age group, since the mid-1970s. Progress has been slower since the 1980s, underscoring why research into new treatment approaches continues.

Sources

• National Cancer Institute – SEER Cancer Stat Facts: Bone and Joint Cancer
• National Cancer Institute – Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version
• National Cancer Institute – Ewing Sarcoma Treatment (PDQ®)–Health Professional Version
• National Cancer Institute – Primary Bone Cancer